TouchONCOLOGY got the chance to catch up with Dr Evan Lipson (Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA) around the RELATIVITY-047 study, which investigated the combined therapy of relatlimab plus nivolumab in patients with advanced melanoma.
The abstract ‘Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)‘ (abstract number 9503) was presented at the 2021 ASCO Annual Meeting.
Questions
- Could you tell us a little about relatlimab, and the rationale for using it in combination with nivolumab in the treatment of advanced melanoma? (0:22)
- What were the aim, design and clinical endpoints of the RELATIVITY-047 study? (1:21)
- How well were survival and safety endpoints met? (2:38)
- Which subgroups were most likely to benefit from this combined therapy? (3:39)
- How do these findings compare with those of the Checkmate-067 study? (4:06)
- What were the conclusions from the study and how do the findings influence the future treatment landscape? (4:50)
Disclosures: Advisory Board (Personal): Bristol Myers-Squibb, Novartis, EMD Serono, Array BioPharma, Merck, Sanofi, Regeneron, Genentech, Odonate Therapeutics; Consultant/ Other (Personal): Macrogenics; Local PI (No financial interest, Institutional): Regeneron, Merck; Coordinating PI (No financial interest, Institutional): Bristol-Myers Squibb.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the 2021 ASCO Annual Meeting.
